| 2,449 | 54 | 103 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:借助网络药理学研究模式,以中医理论为指导原则,从分子水平探究六味地黄丸对高血压、2型糖尿病、阿尔茨海默病"异病同治"的物质基础和作用机制。方法:使用TCMSP、Swiss Target Prediction、STITCH数据库筛选出六味地黄丸的化学成分及其作用靶点,结合从Genecards、HPO、OMIM数据库以及GEO数据库中获取的基因芯片挖掘出的疾病靶点,将二者取交集后获取的共有靶点导入STRING数据库获得蛋白质相互作用关系,运用Cytoscape软件构建"中药-化合物-靶点"网络及PPI网络,运用Auto Dock软件进行分子对接。最后借助DAVID数据库进行GO和KEGG富集分析。结果:筛选出六味地黄丸活性成分69个,作用靶点280个,高血压、2型糖尿病、阿尔茨海默病及六味地黄丸共有靶点如VEGFA、IL-6、MMP-9、PPARG等21个。结论:该研究初步揭示了六味地黄丸对三病"异病同治"作用的现代生物学机制,包括影响血管生成及内皮功能、炎症反应、缺氧反应,为探究中医"异病同治"治疗原则的科学内涵提供了一定的依据。
Abstract：Objective: This paper was to explore the common mechanisms of LiuWei DiHuang Pill(LWDH Pill) in treating Hypertension, Type 2 diabetes mellitus and Alzheimer's disease under the guidance of traditional Chinese medicine theory based on network pharmacology. Methods: TCMSP, Swiss Target Prediction, STITCH databases were used to screen out the chemical components and its potential targets of LWDH Pill, then disease targets were obtained from Genecards, HPO and OMIM databases to achieve gene chip. By combining the two targets to obtain common targets and importing them into the STRING database, a protein interaction relationship was established and "Chinese medicine-compound-target" network and PPI network were constructed by Cytoscape software. Then we used Auto Dock software for molecular docking. Finally, DAVID database was used for GO and KEGG enrichment analysis. Results: 69 active ingredients and 280 targets were collected from LWDH Pill, 21 common targets including VEGFA、IL-6、MMP-9、PPARG from Hypertension, Type 2 diabetes mellitus, Alzheimer's disease and LWDH Pill were screened out. Conclusion: This study preliminarily reveals the modern biological mechanism of LWDH Pill in treating three diseases, including angiogenesis and endothelial function, inflammatory reaction and hypoxia reaction. It provides a certain basis for exploring the scientific connotation of the principle of "treating different diseases with the same treatment" in traditional Chinese medicine.
[1]Wang ZW,Chen Z,Zhang LF,et al.Status of Hypertension in China:Results From the China Hypertension Survey,2012-2015[J].Circulation,2018,137(22):2344-2356.
[2]中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志2018,38(4):292-344.
[3]Joe E,Ringman JM.Cognitive symptoms of Alzheimer's disease:clinical management and prevention[J].BMJ,2019,12(6):l6217.
[4]何珂，朱丽华，陆西宛.六味地黄丸联合二甲双胍片治疗2型糖尿病临床疗效观察[J].中成药，2016,38(1):50-52.
[5]吴梅艳，李平.六味地黄丸的药理作用及临床运用综述[J].世界中西医结合杂志，20149,(9):1023-1025.
[6]刘巍，熊兴江，王阶.论六味地黄丸在高血压病治疗中的运用[J].中华中医药杂志，2013,28(11):3329-3333.
[7]杜亚明，李祥华，张家均.六味地黄丸对2型糖尿病大鼠胰岛素抵抗的影响[J].中药药理与临床，2012,28(6):6-9.
[8]朱仲康，张林，柳春，等.补肾填精法对肾虚阿尔茨海默小鼠海马自噬的干预作用[J].中国实验方剂学杂志，2019,25(20):43-48.
[9]Wang J H,Zhang X R,Cheng X R,et al.LW-AFC,A New Formula Derived from Liuwei Dihuang Decoction,Ameliorates Cognitive Deterioration and Modulates Neuroendocrine-Immune System in SAMP8 Mouse[J] .Curr Alzheimer Res,2017,14(2):221-238.
[10]李梢.网络靶标：中药方剂网络药理学研究的一个切入点[J].中国中药杂志，2011,36(15):2017-2020.
[11]刘志强，王博龙.中药网络药理学药效成分筛选与靶标预测的研究进展[J].中成药，2019,41(1):171-178.
[12]孙凯滨，孙蓉.基于网络药理学研究模式的柴胡桂枝汤治疗胃溃疡与癫痫的异病同治分析[J].中草药，2019,50(21):5178-5186.
[13]吴丹，高耀，向欢，等.逍遥散“异病同治”抑郁症和糖尿病的网络药理学作用机制研究[J].中草药，2019,50(8):1818-1827.
[14]Huang C,Yang Y,Chen X,et al.Large-scale cross-species chemogenomic platform proposes a new drug discovery strategy of veterinary drug from herbal medicines[J].PLoS ONE,2017,12(9):e0184880.
[15]中国高血压防治指南2018年修订版[J].心脑血管病防治，2019,19(1):1-44.
[16]Liu J,Zhao D,Liu J,et al.Prevalence of diabetes mellitus in outpatients with essential hypertension in China:a cross-sectional study[J].BMJ Open,2013,3(11):e003798.
[17]Iadecola C,Yaffe K,Biller J,et al.Impact of Hypertension on Cognitive Function:A Scientific Statement From the American Heart Association[J].Hypertension,2016,68(6):e67-e94.
[18]Power M C,Weuve J,Gagne J J,et al.The association between blood pressure and incident Alzheimer disease:a systematic review and meta-analysis[J].Epidemiology,2011,22(5):646-659.
[19]Biessels GJ,Staekenborg S,Brunner E,et al.Risk of dementia in diabetes mellitus:a systematic review[J].Lancet Neurol,2006,5(1):64-74.
[20]Kopf D,Fr?lich L.Risk of incident Alzheimer's disease in diabetic patients:a systematic review of prospective trials[J].J.Alzheimers Dis.,2009,16(4):677-685.
[21]Moreno-Gonzalez I,Edwards IG,Salvadores N,et al.Molecular interaction between type 2 diabetes and Alzheimer's disease through cross-seeding of protein misfolding[J].Mol.Psychiatry,2017,22(9):1327-1334.
[22]徐佩英，吴铱达.糖尿病合并高血压的临床特征及其中医证候[J].中国临床医学，2012,19(3):329-330.
[23]孙国珺，顾耘，黄凯，等.阿尔茨海默病中医证候研究[J].中华中医药学刊，2014,32(7):1566-1568.
[24]孙雨薇，朱丽，李宇佳.六味地黄丸在肝肾阴虚证治疗中的药理作用及应用效果[J].中国现代药物应用，2019,13(19):111-112.
[25]赵艳萍，曾良帮，张俊，等.老年原发性高血压患者血管结构及功能与靶器官损害的关系研究[J].四川大学学报(医学版),2019,50(6):901-905.
[26]Wang Y,Rijal B,Xu M,et al.Renal denervation improves vascular endothelial dysfunction by inducing autophagy via AMPK/mTOR signaling activation in a rat model of type 2 diabetes mellitus with insulin resistance[J].Acta Diabetol,2020,57(10):1227-1243.
[27]魏聪，申锷，胡兵.糖尿病大血管病变的研究进展[J].上海交通大学学报(医学版),2010,30(10):1292-1296.
[28]Religa P,Cao R,Religa D,et al.VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival[J].Sci Rep,2013(3):2053.
[29]韩娜，刚宝芝.阿尔茨海默病退行性病变和血管因素复合损伤及血管内皮生长因子的作用[J].医学综述，2012,18(17):2740-2743.
[30]傅为武，欧阳雅蓉，黄彩依，等.基于高血压炎症反应探讨高血压治疗研究进展[J/OL].海南医学院学报：1-5[2020-07-18].https://doi.org/10.13210/j.cnki.jhmu.20200617.001.
[31]Hotamisligil GS.Inflammation and metabolic disorders[J].Nature,2006,444(7121):860-867.
[32]宋晨萌，赵海峰.多酚类化合物防治阿尔茨海默病的机制[J].卫生研究，2020,49(3):523-526.
[33]Zhang W,Wang W,Yu H,et al.Interleukin 6 underlies angiotensinⅡ-induced hypertension and chronic renal damage[J].Hypertension,2012,59 (1) :136-144.
[34]张黎明，高凌.炎症细胞因子在2型糖尿病发病机制中的研究进展[J].重庆医学，2016,45(8):1113-1116.
[35]Kong X J,Gong Z,Zhang L,et al.JAK2/STAT3 signaling mediates IL-6-inhibited neurogenesis of neural stem cells through DNA demethylation/methylation[J].Brain Behav.Immun.,2019,(79):159-173.
[36]Anna C,Kurkowska-Jastrzebska I.The role of inflammatory reaction in Alzheimer's disease and neurodegenerative processes[J].Neurologia I Neurochirurgia Polska,2002,36(1):15-23.
[37]Shenoy N,Pagliaro L.Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma:putting it together with a translational perspective[J].Ann.Oncol,2016,27(9):1685-1695.
[38]Xu X F,Liu T,Wu J,et al.Transferrin receptor-involved HIF-1 signaling pathway in cervical cancer[J].Cancer Gene Ther,2019,(26):356-365.
[39]王苹苹，孔繁平，陈学群，等.低氧细胞应激的HIF-1信号通路[J].浙江大学学报(医学版),2011,40(5):559-566.
[40]魏建行，李利华.低氧诱导因子HIF-1α与高血压关系的研究进展[J].中国高原医学与生物学杂志，2018,39(4):276-281.
[41]Gautier-Stein A,Soty M,Chilloux J,et al.Glucotoxicity induces glucose-6-phosphatase catalytic unit expression by acting on the interaction of HIF-1α with CREB-binding protein[J].Diabetes,2012,61(10):2451-2460.
[42]Desmond DW,Moroney JT,Sano M,et al.Incidence of dementia after ischemic stroke:results of a longitudinal study[J].Stroke,2002,33(9):2254-2260.
[43]陈娟，王蓉.缺氧与AD发病机制的关系[J].军医进修学院学报，2012,33(5):547-549.
[44]王梦楠，刘军红，张瑞芳，等.厄贝沙坦联合六味地黄丸对阴虚阳亢型原发性高血压伴早期肾损害病人炎性因子的影响[J].中西医结合心脑血管病杂志，2020,18(4):635-638.
[45]杜静静，黄平.六味地黄丸对TNF-α、IL-6表达水平的影响及糖尿病肾病大鼠肾脏的保护机制研究[J].现代中医药，2014,34(1):74-77.
[46]冯炯，臧敏.六味地黄丸对痴呆模型小鼠学习记忆及细胞因子的影响[J].山东中医杂志，2010,(4):264-265.
[47]于洋，赵宁，张娜.六味地黄丸对糖尿病大鼠血管功能的影响及抗氧化应激机制[J].中国老年学杂志，2018,38(11):2712-2715.
[48]宋军营，袁永，王丛笑，等.六味地黄丸含药血清对β-淀粉样蛋白损伤大鼠肾上腺嗜铬细胞瘤细胞的保护作用研究[J].中国全科医学，2017,20(30):3763-3769.
[49]He H B,Yang X Z,Zeng X W,et al.Protective effect of Liuwei Dihuang decoction on early diabetic nephropathy induced by streptozotocin via modulating ET-ROS axis and matrix metalloproteinase activity in rats[J].J.Pharm.Pharmacol.,2007,59(9):1297-1305.
[50]贺福元，邓凯文，刘文龙，等.中药复方网络药理学及其动力学关键技术问题的探讨[J].中药药理与临床，2012,28(5):256-259,17.
基本信息:
DOI：10.13412/j.cnki.zyyl.20201214.005
中图分类号:R285
引用信息:
[1]郭航,赵春燕,战丽彬,等.基于网络药理学的六味地黄丸治疗高血压、2型糖尿病、阿尔茨海默病的异病同治机制分析[J].中药药理与临床,2021,37(01):41-49.DOI:10.13412/j.cnki.zyyl.20201214.005.
基金信息:
国家重点研发计划资助(编号：2018YFC1704400)
2020-12-14
2020-12-14
2020-12-14